Journal
MEDICINAL RESEARCH REVIEWS
Volume 30, Issue 1, Pages 23-66Publisher
WILEY
DOI: 10.1002/med.20161
Keywords
angiogenesis; metastasis; antivascular agents; prostate cancer
Categories
Funding
- Australian Research Council (ARC)
- Cancer Institute NSW
Ask authors/readers for more resources
It is becoming increasingly clear that angiogenesis plays a crucial role in prostate cancer (CaP) survival, progression, and metastasis. Tumor angiogenesis is a hallmark of advanced cancers and an attractive treatment target in multiple solid tumors. By understanding the molecular basis of resistance to androgen withdrawal and chemotherapy in CaP, the rational design of targeted therapeutics is possible. This review summarizes the recent advancements that have improved our understanding of the role of angiogenesis in CaP metastasis and the potential therapeutic efficacy of inhibiting angiogenesis in this disease. Current therapeutic options for patients with metastatic hormone-refractory CaP are very limited. Targeting vasculature is a developing area, which shows promise for the control of late stage and recurrent CaP disease and for overcoming drug resistance. We discuss angiogenesis and its postulated mechanisms and focus on the regulation of angiogenesis in CaP progression and the therapeutic beneficial effects associated with targeting of the CaP vasculature to overcome the resistance to current treatments and CaP recurrence. (C) 2009 Wiley Periodicals, Inc. Med Res Rev, 30. No. 1, 23-66, 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available